Schedule 13D ownership disclosure
Keenova Therapeutics PLC
Ordinary Shares, par value $0.01 per share · CUSIP: G5890A102
Event date: 2026-11-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- GoldenTree Asset Management LPReported CIK 0001278951
Shares: 8,821,928.00 · Class: 22.3%
- GoldenTree Asset Management LLCReported CIK 0001435627
Shares: 8,821,928.00 · Class: 22.3%
- Steven A. TananbaumReported CIK 0001435626
Shares: 8,875,543.00 · Class: 22.4%
- GoldenTree Master Fund, Ltd.
Shares: 2,510,139.00 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-26-051012
- Form type
- SCHEDULE 13D/A
- Filer
- Keenova Therapeutics plc
- CIK
- CIK 1567892
- Filed
- Nov 10, 2026
- Reporting period
- Nov 06, 2026
- Description
- Schedule 13D beneficial ownership